Tags : Diseases

Henlius Signs a License Agreement with Essex to Co-develop HLX04

Shots: Henlius to receive upfront, regulatory, and commercial milestone payments of ~$43M, eligible to receive $30M for every $1B above the first $600M of the cumulative net sales along with 10% royalties on net sales of the therapy Henlius will be responsible for the pre/ clinical development of HLX04, whereas Essex is responsible for regulatory […]Read More

Genentech Collaborates with Imbio to Develop Imaging Diagnostics for Lung

Shots: The agreement leverages Imbio’s technical, regulatory & commercial expertise to build medical imaging AI technology for use in research, clinical trials & clinical practice The focus of the agreement is to develop quantitative imaging diagnostics for lung diseases and to bring unique solutions for pulmonary imaging. The collaboration integrates Imbio’s expertise in imaging biomarkers […]Read More

AstraZeneca Collaborates with Eko to Advance the Digital Health Tools

Shots: The two companies collaborated to facilitate the development of digital health tools for the earlier screening of cardiovascular diseases, including HF AstraZeneca and Eko will accelerate the development of Eko algorithms, enhancing clinical trials with Eko technology, and potentially building new HF detection solutions. The agreement allows the companies to harness the potential to […]Read More

Bayer Signs a Three Year Multi Target AI-based Agreement with

Shots: Exscientia to get up to $266.2M including upfront, research payments and clinical milestones plus royalties on sales. Bayer to get rights for the developed therapies under collaboration   The partners will focus on early research projects combining Exscientia’s AI drug discovery platform and drug design know-how with Bayer’s data and drug discovery capabilities for […]Read More

BioMed Collaborates with Merck & Co for Autoimmune Diseases

Shots: BioMed and Merck & Co (MSD outside the United States and Canada) signs an agreement and extends their ongoing collaboration for six joint research projects at BioMed X Innovation Center in Heidelberg, Germany The focus of the agreement is to concentrate on the role of intestinal epithelial barrier in the development and exacerbation of […]Read More

Genentech Signs an Exclusive Option and License Agreement with Skyhawk

Shots: Skyhawk to receive up front, more than $2B as option fee & milestones, royalties on sales and will utilize its SkySTAR technology platform to discover and develop RNA splicing modifiers targeting oncology & neurological disorders Genentech to get an exclusive WW license to develop & commercialize RNA splicing modifiers targeting neurodegenerative diseases and cancer […]Read More

Baxter’s Eptifibatide Receives the US FDA’s Approval for Cardiovascular Diseases

Shots: Baxter’s ready to use Eptifibatide is approved and launched for patients with acute coronary syndrome (ACS) & percutaneous coronary intervention (PCI) The FDA approval strengthens Baxter’s premix portfolio, enhance patient’s safety by avoiding dosing error and reduces the burden on hospital pharmacist Eptifibatide (75mg/100ml) is a platelet aggregation inhibitor, based on Baxter’s galaxy container […]Read More